Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer

NCT ID: NCT02340949

Last Updated: 2021-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2020-02-04

Brief Summary

This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in order to evaluate the efficacy in terms of pathologic complete response (pCR).

Detailed Description

This is a randomized trial comparing induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery. Once it is confirmed that the subjects fulfill the eligibility criteria (MRI-defined high risk RC), and have signed the informed consent, a central review will be requested to confirm clinical stage, and then they will be randomized to receive mFOLFOX6 + Aflibercept or mFOLFOX6 (without Aflibercept).

Random assignment of treatment will be stratified by T3 versus T4 stage. All the patients enrolled in the study will receive one cycle of study medication (mFOLFOX6 with or without aflibercept) every 14 days for six cycles, unless unacceptable toxicity or progression is detected. After this treatment, patients will receive standard chemo-radiotherapy (CT/RT) (capecitabine 825 mg/m2 twice daily combined with a total dose of 50.4 Gy in 28 days) followed by surgery, provided they have not progressed.

Patients with progression disease during the treatment phase will be withdrawn from the study and will receive their treatment according to the investigator's judgment. If a patient withdraws consent and refuses to receive further treatment, the patient must be followed up for 3 years from randomization or until progression, to evaluate disease-free survival. If a patient withdraws consent and refuses to continue in the study, the follow-up evaluations must be discontinued.

Conditions

Rectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

mFOLFOX6 + Aflibercept

• mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:

Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².

• Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.

Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs.

Group Type: EXPERIMENTAL

Aflibercept

Intervention Type: DRUG

Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml

5-Fluoruracil

Intervention Type: DRUG

Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2

Oxaliplatin

Intervention Type: DRUG

Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU

Leucovorin

Intervention Type: DRUG

Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU

mFOLFOX6

• mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:

Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².

Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs.

Group Type: ACTIVE_COMPARATOR

5-Fluoruracil

Intervention Type: DRUG

Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2

Oxaliplatin

Intervention Type: DRUG

Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU

Leucovorin

Intervention Type: DRUG

Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU

Interventions

Aflibercept

Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml

Intervention Type: DRUG

5-Fluoruracil

Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2

Intervention Type: DRUG

Oxaliplatin

Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU

Intervention Type: DRUG

Leucovorin

Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU

Intervention Type: DRUG

Other Intervention Names

ZALTRAP; 5-FU; Any marketed; Any marketed

Eligibility Criteria

Inclusion Criteria

1. Signed and dated informed consent, and willing and able to comply with protocol requirement;

2. Male or female subjects with rectal cancer ≥18 and <70 years of age;

3. High risk MRI-defined operable rectal cancer (with an inferior margin no more than 12 cm above the anal verge as assessed by MRI). Presence of at least 1 of the following on high resolution, thin-slice MRI (3 mm):

Middle Third Tumors

• mr T3

1. Extramural vascular invasion (EMVI) positive

2. Extramural extension > 5 mms into perirectal fat

3. Mesorectal fascia (MRF) threatened or involved*

• mr T4***

Distal Third Tumors (≤5 cm from anal verge)

• mr T3 tumor at or below levators
• T4 as above N2**

• tumor or lymph node < 1 mm from the mesorectal fascia **≥4 lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease. ≥4 nodes, whether enlarged or not, with a rounded, homogeneous appearance is thus not sufficient.

• T4a: overgrowth to an adjacent organ or structure or T4b: peritoneal involvement.

4. Histologically confirmed adenocarcinoma of the rectum. All other histological types are excluded;

5. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1;

6. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; hemoglobin ≥9g/dL;

7. Adequate renal function: serum creatinine level <1.5 x upper limit of normality (ULN);

8. Adequate liver function: serum bilirubin ≤1.5 x ULN, alkaline phosphatase <5x ULN, AST/ALT < 3 x ULN;

9. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour;

10. Regular follow-up feasible;

11. For female patients of childbearing potential, negative serum pregnancy test within 1 week (7 days) prior to starting study treatment;

12. Female patients must commit to using reliable and appropriate methods of contraception until at least three months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial.

Exclusion Criteria

1. Prior treatment with aflibercept;

2. History or evidence upon physical examination of metastasis;

3. Uncontrolled hypercalcemia;

4. Pre-existing permanent neuropathy (NCI grade ≥2);

5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy;

6. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy);

7. Treatment with any other investigational medicinal product within 28 days prior to study entry;

8. Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years;

9. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days;

10. Pregnant or breastfeeding women;

11. Patients with known allergy to any excipient to study drugs;

12. History of myocardial infarction and/or stroke within 6 months prior to randomization; Previous history of stable angina, uncontrolled arrhythmia, and acute coronary syndrome even if controlled with medication or with myocardial infarction within the last 12 months.

13. Bowel obstruction.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 69 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pivotal S.L.

INDUSTRY

Sponsor Role: collaborator

Grupo Espanol Multidisciplinario del Cancer Digestivo

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Carlos Fernández-Martos, MD

Role: STUDY_DIRECTOR

Fundación Instituto Valenciano de Oncología

Antonieta Salud Salvia, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitari Arnau de Vilanova de Lleida

Carles Pericay Pijaume, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital de Sabadell - Parc Taulí

Clara Montagut, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital del Mar

Joan Maurel Santasusana, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Clinic i provincial de Barcelona

Vicente Alonso Orduña, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Miguel Servet

Ruth Vera García, MD

Role: PRINCIPAL_INVESTIGATOR

Complejo Hospitalario de Navarra

Javier Gallego Plazas, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital General Universitario de Elche

Núria Rodríguez Salas, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario La Paz

Antonio Cubillo, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Madrid Sanchinarro (CIOCC)

Bertomeu Massuti, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital General Universitario de Alicante

Ferrán Losa, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital de Sant Joan Despí Moisés Broggi

Miguel Nogué, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital General de Granollers

Jaume Capdevila, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitari Vall d'Hebrón

Isabel Busquier, MD

Role: PRINCIPAL_INVESTIGATOR

Consorcio Hospitalario Provincial de Castellón

Inma Guash Jordan, MD

Role: PRINCIPAL_INVESTIGATOR

Fundación Althaia Manresa

Laura Layos Romero, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitari Germans Trias i Pujol de Badalona

Marta Martín-Richard, MD

Role: PRINCIPAL_INVESTIGATOR

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Rocio García Carbonero, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario 12 de Octubre

Carlos López López, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Marqués de Valdecilla

References

Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 1;5(11):1566-1573. doi: 10.1001/jamaoncol.2019.2294.

Reference Type: DERIVED

PMID: 31465088 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

GEMCAD-1402

Identifier Type: -

Identifier Source: org_study_id